Skba Capital Management LLC Increases Stake in Kenvue Inc. (NYSE:KVUE)

Skba Capital Management LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 6.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 601,330 shares of the company’s stock after acquiring an additional 36,070 shares during the quarter. Kenvue makes up about 2.0% of Skba Capital Management LLC’s portfolio, making the stock its 14th biggest holding. Skba Capital Management LLC’s holdings in Kenvue were worth $12,838,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in KVUE. Grove Bank & Trust lifted its holdings in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in Kenvue during the 4th quarter worth approximately $29,000. SRS Capital Advisors Inc. raised its holdings in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after buying an additional 571 shares during the last quarter. Fortitude Family Office LLC lifted its holdings in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc boosted its holdings in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Up 1.0 %

KVUE opened at $23.74 on Monday. The company’s 50 day moving average is $22.32 and its 200-day moving average is $22.45. The company has a market cap of $45.36 billion, a P/E ratio of 44.78, a PEG ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.45%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

KVUE has been the subject of a number of recent research reports. Citigroup lowered their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Piper Sandler boosted their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Evercore ISI began coverage on shares of Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 price target for the company. Canaccord Genuity Group boosted their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Finally, UBS Group reduced their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.